» Articles » PMID: 34496965

Resistin Levels and Inflammatory and Endothelial Dysfunction Markers in Obese Postmenopausal Women with Type 2 Diabetes Mellitus

Overview
Publisher Biomed Central
Specialty Endocrinology
Date 2021 Sep 9
PMID 34496965
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Obesity-associated coronary heart disease (CHD) risk is higher in women than in men with type 2 diabetes (T2DM). Resistin, an adipokine secreted by adispose tissue, may contribute to this higher risk.

Aims: To explore the relationships among resistin levels and common inflammatory and endothelial dysfunction markers and CHD risk in obese post-menopausal T2DM women.

Methods: Serum levels of resistin, hsCRP, IL-6, Soluble vascular cell adhesion molecule (sVCAM), homocysteine (tHcy), HOMA-IR and metabolic parameters were determined in a group of 132 T2DM women with and without documented CHD and in 55 non-diabetic women.

Results: Resistin, sVCAM, IL-6 and tHcy levels were comparable in T2DM and controls. CHD women showed higher resistin, sVCAM and tHcy levels than those without CHD, and for resistin this difference remained significant after age-adjustment (P = 0.013); conversely hsCRP were ~ 2X higher in T2DM women than in controls (P = 0.0132) without any difference according to CHD history. At univariate analysis resistin levels were significantly associated with age, waist circumference, hypertension, tHcy, hsPCR, sVCAM, IL-6, HDL-cholesterol, triglycerides and creatinine levels, but only creatinine, triglycerides, hsCRP, IL-6 and sVCAM were independently associated to resistin levels at stepwise regression analysis. Resistin levels were independently associated to CHD, increasing the risk by 1.15 times (0.986-1.344 95% CI), together with age, tHcy, LDL-C and hypertension.

Conclusions: Circulating resistin levels were comparable in obese/overweight T2DM and control women. In T2DM women, resistin levels correlated with markers of renal function, systemic inflammation and endothelial dysfunction and were independently associated with a higher CHD risk.

Citing Articles

Adipokines and Cardiometabolic Heart Failure with Preserved Ejection Fraction: A State-of-the-Art Review.

Theodorakis N, Kreouzi M, Hitas C, Anagnostou D, Nikolaou M Diagnostics (Basel). 2024; 14(23).

PMID: 39682585 PMC: 11640255. DOI: 10.3390/diagnostics14232677.


The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity.

Kopczynska J, Kowalczyk M Front Immunol. 2024; 15:1380476.

PMID: 38605957 PMC: 11008232. DOI: 10.3389/fimmu.2024.1380476.


Prospective Association of Circulating Adipokines with Cardiometabolic Risk Profile Among Women: The Rape Impact Cohort Evaluation Study.

Vuong E, Peer N, Chirwa E, Mhlongo S, Lombard C, Hemmings S Womens Health Rep (New Rochelle). 2022; 3(1):820-833.

PMID: 36340478 PMC: 9629977. DOI: 10.1089/whr.2022.0069.


Obesity: A Doorway to a Molecular Path Leading to Infertility.

Ahmad R, Haque M Cureus. 2022; 14(10):e30770.

PMID: 36320802 PMC: 9612950. DOI: 10.7759/cureus.30770.


Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells, Obesity and the Tumor Microenvironment of Breast Cancer.

Ritter A, Kreis N, Hoock S, Solbach C, Louwen F, Yuan J Cancers (Basel). 2022; 14(16).

PMID: 36010901 PMC: 9405791. DOI: 10.3390/cancers14163908.


References
1.
Russo G, Giandalia A, Romeo E, Marotta M, Alibrandi A, De Francesco C . Lipid and non-lipid cardiovascular risk factors in postmenopausal type 2 diabetic women with and without coronary heart disease. J Endocrinol Invest. 2014; 37(3):261-8. DOI: 10.1007/s40618-013-0023-z. View

2.
Farooq R, Amin S, Hayat Bhat M, Malik R, Wani H, Majid S . Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs. Gynecol Endocrinol. 2016; 33(1):75-78. DOI: 10.1080/09513590.2016.1207165. View

3.
Russo G, Pintaudi B, Giorda C, Lucisano G, Nicolucci A, Cristofaro M . Age- and Gender-Related Differences in LDL-Cholesterol Management in Outpatients with Type 2 Diabetes Mellitus. Int J Endocrinol. 2015; 2015:957105. PMC: 4383267. DOI: 10.1155/2015/957105. View

4.
Russo G, Giandalia A, Romeo E, Muscianisi M, Ruffo M, Alibrandi A . HDL subclasses and the common CETP TaqIB variant predict the incidence of microangiopatic complications in type 2 diabetic women: A 9years follow-up study. Diabetes Res Clin Pract. 2017; 132:108-117. DOI: 10.1016/j.diabres.2017.07.026. View

5.
Jung H, Youn B, Cho Y, Yu K, Park H, Shin C . The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism. 2005; 54(3):314-20. DOI: 10.1016/j.metabol.2004.05.019. View